R01CA235612
Project Grant
Overview
Grant Description
Clinical brain tumor development of a cytomegalovirus-targeted therapeutic with vaccine pre-conditioning to validate novel predictors of vaccine efficacy.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27705
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been shortened from 11/30/23 to 07/31/23 and the total obligations have increased 371% from $413,970 to $1,951,674.
Duke University was awarded
Project Grant R01CA235612
worth $1,951,674
from National Cancer Institute in December 2018 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 4 years 7 months and
was awarded through assistance program 93.395 Cancer Treatment Research.
The Project Grant was awarded through grant opportunity National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required).
Status
(Complete)
Last Modified 3/5/24
Period of Performance
12/1/18
Start Date
7/31/23
End Date
Funding Split
$2.0M
Federal Obligation
$0.0
Non-Federal Obligation
$2.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01CA235612
Additional Detail
Award ID FAIN
R01CA235612
SAI Number
R01CA235612-1404580483
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
TP7EK8DZV6N5
Awardee CAGE
4B478
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,813,353 | 100% |
Modified: 3/5/24